Study on the interactions between transplanted bone marrow-derived mesenchymal stem cells and regulatory T cells for the treatment of experimental colitis

Zuo,Dongmei; Liu,Xingxing; Shou,Zhexing; Fan,Heng; Tang,Qing; Duan,Xueyun; Cao,Dan; Zou,Zhou; Zhang,Lijuan

doi:10.3892/ijmm.2013.1529

Study on the interactions between transplanted bone marrow-derived mesenchymal stem cells and regulatory T cells for the treatment of experimental colitis

Authors:
- Dongmei Zuo
- Xingxing Liu
- Zhexing Shou
- Heng Fan
- Qing Tang
- Xueyun Duan
- Dan Cao
- Zhou Zou
- Lijuan Zhang
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, Hubei College of Traditional Chinese Medicine (TCM), Wuhan, Hubei, P.R. China
Published online on: October 16, 2013 https://doi.org/10.3892/ijmm.2013.1529
Pages: 1337-1344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has established the use of mesenchymal stem cells (MSCs) as candidate cells for immunosuppressive therapy. Experimental studies have suggested that MSCs exert their immunomodulatory effects through the induction of regulatory T cells (Tregs) in vitro and in vivo. However, the interactions between MSCs and Tregs in inflammatory bowel disease (IBD) and whether MSCs can be used for the treatment of IBD remains to be elucidated. In this study, we aimed to investigate whether MSCs can be used for the treatment of IBD through the induction of Tregs. MSCs were isolated and identified by flow cytometry. The MSCs were transduced with a replication-defective recombinant lentiviral vector carrying GFP in order to be able to trace the injected cells in vivo. Prepared MSCs (1x106) were injected into rats with 2,4,6-trinitrobenzene sulfonic acid (TNBS)‑induced colitis via the tail vein; the control rats received phosphate-buffered saline (PBS) alone. Two weeks after the intravenous infusion, the frequency of CD4+CD25+Foxp3 cells in the peripheral blood was examined by flow cytometry. The colon was sectioned and analyzed for histopathological changes. Foxp3 mRNA expression was determined by real-time reverse-transcription polymerase chain reaction (qRT-PCR). In our study, the systemic infusion of MSCs significantly ameliorated the clinical and histopathologic severity of TNBS-induced colitis in contrast to the controls. There was an inverse regulation of mucosal and peripheral Foxp3 expression, suggesting that the MSCs redistributed the Tregs from the mucosa to the blood. Thus, MSCs exhibit immunomodulatory functions and may be used to ameliorate or treat IBD by redistributing regulatory T cells. Therefore, the interactions between transplanted bone marrow-derived MSCs and Tregs should be further investigated; MSCs have tremendous potential for use in the treatment of IBD.

View Figures

View References

1	Baumgart DC and Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–1640. 2007. View Article : Google Scholar : PubMed/NCBI
2	Bouma G and Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 3:521–533. 2003. View Article : Google Scholar : PubMed/NCBI
3	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar
4	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
5	Himmel ME, Hardenberg G, Piccirillo CA, et al: The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 125:145–153. 2008. View Article : Google Scholar : PubMed/NCBI
6	Fiocchi C: Towards a ‘cure’ for IBD. Dig Dis. 30:428–433. 2012.
7	Shevach EM: Mechanisms of foxp3⁺ T regulatory cell-mediated suppression. Immunity. 30:636–645. 2009.
8	Wing K and Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 11:7–13. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bacchetta R, Passerini L, Gambineri E, et al: Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 116:1713–1722. 2006. View Article : Google Scholar : PubMed/NCBI
10	McMurchy AN, Di Nunzio S, Roncarolo MG, et al: Molecular regulation of cellular immunity by FOXP3. Adv Exp Med Biol. 665:30–46. 2009. View Article : Google Scholar : PubMed/NCBI
11	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
12	Mottet C, Uhlig HH and Powrie F: Cutting edge: cure of colitis by CD4⁺CD25⁺ regulatory T cells. J Immunol. 170:3939–3943. 2003. View Article : Google Scholar : PubMed/NCBI
13	Yi T and Song SU: Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 35:213–221. 2012. View Article : Google Scholar : PubMed/NCBI
14	Potian JA, Aviv H, Ponzio NM, et al: Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 171:3426–3434. 2003. View Article : Google Scholar
15	Le Blanc K, Tammik C, Rosendahl K, et al: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 31:890–896. 2003.PubMed/NCBI
16	Engela AU, Baan CC, Dor FJ, et al: On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol. 3:1262012. View Article : Google Scholar : PubMed/NCBI
17	Le Blanc K, Frassoni F, Ball L, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 371:1579–1586. 2008.
18	Dalal J, Gandy K and Domen J: Role of mesenchymal stem cell therapy in Crohn’s disease. Pediatr Res. 71:445–451. 2012.
19	Sun S, Guo Z, Xiao X, et al: Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells. 21:527–535. 2003. View Article : Google Scholar : PubMed/NCBI
20	Morris GP, Beck PL, Herridge MS, et al: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:795–803. 1989.PubMed/NCBI
21	Vowinkel T, Kalogeris TJ, Mori M, et al: Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 49:556–564. 2004. View Article : Google Scholar : PubMed/NCBI
22	González R, Rodríguez S, Romay C, et al: Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Parmacol Res. 39:55–59. 1999.
23	Powrie F, Correaoliveira R, Mauze S, et al: Regulatory interactions between Cd45Rb(high) and Cd45Rb(low) Cd4(+) T-cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med. 179:589–600. 1994.
24	Read S, Malmstrom V and Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 192:295–302. 2000.
25	Strober W: Animal models of inflammatory bowel disease - an overview. Dig Dis Sci. 30:3S–10S. 1985. View Article : Google Scholar : PubMed/NCBI
26	Neuman MG: Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 13:309–316. 2004.PubMed/NCBI
27	Reiff C and Kelly D: Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol. 300:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cho JH: The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 8:458–466. 2008. View Article : Google Scholar
29	Chaperon EA, Selner JC and Claman HN: Migration of antibody-forming cells and antigen-sensitive precursors between spleen, thymus and bone marrow. Immunology. 14:553–561. 1968.PubMed/NCBI
30	Sakaguchi S, Sakaguchi N, Asano M, et al: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1151–1164. 1995.
31	Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al: Immunologic self-tolerance maintained by CD25⁺CD4⁺ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 10:1969–1980. 1998.
32	d’Hennezel E, Bin Dhuban K, Torgerson T, et al: The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 49:291–302. 2012.PubMed/NCBI
33	Maloy KJ: Induction and regulation of inflammatory bowel disease in immunodeficient mice by distinct CD4⁺ T-cell subsets. Methods Mol Biol. 380:327–335. 2007. View Article : Google Scholar : PubMed/NCBI
34	Eri R, McGuckin MA and Wadley R: T cell transfer model of colitis: a great tool to assess the contribution of T cells in chronic intestinal inflammation. Methods Mol Biol. 844:261–275. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tolar J, Le Blanc K, Keating A and Blazar BR: Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 28:1446–1455. 2010. View Article : Google Scholar : PubMed/NCBI
36	Casiraghi F, Azzollini N, Cassis P, et al: Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 181:3933–3946. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ge W, Jiang J, Arp J, et al: Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 90:1312–1320. 2010. View Article : Google Scholar : PubMed/NCBI
38	Li Z, Arijs I, De Hertogh G, et al: Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 16:1299–1310. 2010. View Article : Google Scholar : PubMed/NCBI
39	Djouad F, Plence P, Bony C, et al: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 102:3837–3844. 2003. View Article : Google Scholar : PubMed/NCBI
40	Karp JM and Leng Teo GS: Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 4:206–216. 2009. View Article : Google Scholar : PubMed/NCBI